SPONSOR
The First Affiliated Hospital of Xiamen University
Total Trials
9
Recruiting
9
Phases
Phase 2, Phase 1
Conditions studied: Thyroid Eye Disease, TEDGraves OphthalmopathyGraves OrbitopathyAxial SpondyloarthritisTumorPD-L1NSCLCTrop2PET/CTAF - Atrial Fibrillation
The First Affiliated Hospital of Xiamen University is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy, Axial Spondyloarthritis.
The trial portfolio spans Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — The First Affiliated Hospital of Xiamen University
How many clinical trials has The First Affiliated Hospital of Xiamen University sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by The First Affiliated Hospital of Xiamen University, of which 9 are actively recruiting participants. These trials cover conditions including Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does The First Affiliated Hospital of Xiamen University research focus on?
The First Affiliated Hospital of Xiamen University clinical trials span Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy, Axial Spondyloarthritis, Tumor, and additional conditions. The research pipeline includes Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a The First Affiliated Hospital of Xiamen University clinical trial?
To participate in a The First Affiliated Hospital of Xiamen University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all The First Affiliated Hospital of Xiamen University trials with current recruitment status updated daily.
Clinical Trials by The First Affiliated Hospital of Xiamen University
NCT07547930 Phase 2
Recruiting
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Thyroid Eye Disease, TED
NCT03425812
Recruiting
Effects of Nonsteroidal Anti-Inflammatory Drugs in Recurrence of Spondyloarthritis Patients After Remission
Axial Spondyloarthritis
NCT06754345
Recruiting
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
Tumor
NCT07151898
Recruiting
PET/CT for Trop2 ADC Response Evaluation NSCLC
NSCLC
NCT05841615
Recruiting
Pulmonary Vein Isolation (PVI) Combined With Renal Denervation (RDN) in Atrial Fibrillation (AF) and Hypertension (HTN)
AF - Atrial Fibrillation
NCT06651866 Phase 1
Recruiting
Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients
Acute Myeloid Leukemia
NCT04416165
Recruiting
Comparison of FDG and FAPI in Patients With Various Types of Cancer
Tumor, Solid
NCT06282224
Recruiting
Application of Augmented Reality Neuronavigation in Transnasal Endoscopic Skull Base Surgery
Pituitary Neoplasms
NCT06651853 Phase 2
Recruiting
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Diffuse Large B-cell Lymphoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology